ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 50

Circulating 25(OH)D, LL-37 and Antimicrobial Protein and Peptide (APP) Levels Are Altered Prior to Onset of Rheumatoid Arthritis

Vidyanand Anaparti1, Xiaobo Meng 1, Hemshekhar Mahadevappa 1, Irene Smolik 1, Neeloffer Mookherjee 1 and Hani El-Gabalawy 1, 1University of Manitoba, Winnipeg, MB, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: 25-hydroxyvitamin D, preclinical RA, Rheumatoid arthritis (RA), Vitamin D and Progressors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Etiology & Pathogenesis Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Epidemiological studies suggest vitamin D deficiency as a potential risk factor for rheumatoid arthritis (RA) development, a chronic autoimmune disorder highly prevalent in indigenous North American (INA) population. Vitamin D improves immune function and protects against infections by inducing the expression of antimicrobial proteins and peptides (APPs) such as LL-37. We therefore profiled the circulating levels of 25-hydroxyvitaminD [25(OH)D], an active metabolite of vitamin D, and APPs in serum samples obtained from a cohort of at-risk first-degree relatives (FDR) of INA RA patients, a subset of whom subsequently developed RA (2010 ACR/EULAR guidelines) and were referred as “progressors”.

Methods: 2007 onward, serum samples were collected from at-risk INA FDRs. Anti-citrullinated protein antibodies (ACPA), 25(OH)D, hs-CRP, vitamin-D binding protein (VDBP) and LL-37 (cathelicidin) levels were determined using ELISA and rheumatoid factor (RF) seropositivity was determined by nephelometry. A high-throughput Slow Off-Rate Modified Aptamer (SOMAmer®)-based Protein Array technology (SOMALogic Inc., US) was used for quantification of other APPs.

Results: We demonstrate that seropositive RA patients and FDR had lower 25(OH)D levels compared to ACPA-/FDR (P< 0.05, P< 0.01 respectively). In contrast, serum LL-37 levels were higher in both study groups compared to ACPA-/FDR (P = 0.0009 and P = 0.0120 respectively). No difference was observed in LL-37 levels between ACPA+ FDR and RA patients (P = 0.1090) Linear regression analysis showed circulating 25(OH)D and LL-37 was inversely associated with anti-CCP antibody levels (P = 0.005 and P = 0.05 respectively). Longitudinal samples from 14 progressors demonstrated a consistent increase in 25(OH)D, and LL-37 levels at the time they exhibited clinically detectable joint inflammation, without any significant change in VDBP levels. Expression profile of APPs was also significantly altered in progressors at RA onset and at-risk FDRs.

Conclusion: We demonstrate a differential serum abundance in the levels of 25(OH)D and APPs at RA onset in progressors. The interrelationship between vitamin D and these downstream metabolites and their potential role in RA transition requires further investigation.


Disclosure: V. Anaparti, None; X. Meng, None; H. Mahadevappa, None; I. Smolik, None; N. Mookherjee, None; H. El-Gabalawy, None.

To cite this abstract in AMA style:

Anaparti V, Meng X, Mahadevappa H, Smolik I, Mookherjee N, El-Gabalawy H. Circulating 25(OH)D, LL-37 and Antimicrobial Protein and Peptide (APP) Levels Are Altered Prior to Onset of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/circulating-25ohd-ll-37-and-antimicrobial-protein-and-peptide-app-levels-are-altered-prior-to-onset-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-25ohd-ll-37-and-antimicrobial-protein-and-peptide-app-levels-are-altered-prior-to-onset-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology